Decellularized In Vitro Capillaries for Studies of Metastatic Tendency and Selection of Treatment.
cancer
human adipose stromal cells
human umbilical vein endothelial cells
metastatic niches
patient-derived cancer cells drug screening
tumor microenvironment
vasculature
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
26 Jan 2022
26 Jan 2022
Historique:
received:
17
12
2021
revised:
21
01
2022
accepted:
22
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Vascularization plays an important role in the microenvironment of the tumor. Therefore, it should be a key element to be considered in the development of in vitro cancer assays. In this study, we decellularized in vitro capillaries to remove genetic material and optimized the medium used to increase the robustness and versatility of applications. The growth pattern and drug responses of cancer cell lines and patient-derived primary cells were studied on decellularized capillaries. Interestingly, two distinct growth patterns were seen when cancer cells were grown on decellularized capillaries: "network" and "cluster". Network formation correlated with the metastatic properties of the cells and cluster formation was observed in non-metastatic cells. Drug responses of patient-derived cells correlated better with clinical findings when cells were cultured on decellularized capillaries compared with those cultured on plastic. Decellularized capillaries provide a novel method for cancer cell culture applications. It bridges the gap between complex 3D culture methods and traditional 2D culture methods by providing the ease and robustness of 2D culture as well as an in vivo-like microenvironment and scaffolding for 3D cultures.
Identifiants
pubmed: 35203480
pii: biomedicines10020271
doi: 10.3390/biomedicines10020271
pmc: PMC8869401
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Relander foundation sr.
ID : na
Organisme : Juliana von Wendt foundation
ID : na
Organisme : Business Finland
ID : na
Références
Biotechnol Adv. 2018 Jul - Aug;36(4):1063-1078
pubmed: 29559380
Gynecol Oncol. 2012 Oct;127(1):241-8
pubmed: 22710073
Endocrinology. 2001 Jan;142(1):437-45
pubmed: 11145608
PLoS One. 2012;7(3):e33358
pubmed: 22428030
Tissue Eng Part B Rev. 2016 Feb;22(1):68-100
pubmed: 26447530
Lab Chip. 2018 Nov 6;18(22):3379-3392
pubmed: 30298144
Gynecol Oncol. 2009 Apr;113(1):143-8
pubmed: 19135710
Cancer Lett. 2006 Oct 8;242(1):46-52
pubmed: 16377078
Biol Reprod. 2006 Sep;75(3):387-94
pubmed: 16707768
Cancer Res. 1978 Nov;38(11 Pt 1):3751-7
pubmed: 29704
Cells. 2019 Jan 20;8(1):
pubmed: 30669516
Int J Mol Sci. 2020 Mar 06;21(5):
pubmed: 32155897
PLoS One. 2014 May 08;9(5):e96426
pubmed: 24810913
Int J Mol Sci. 2018 Jul 19;19(7):
pubmed: 30029536
In Vitro Cell Dev Biol Anim. 1999 Jul-Aug;35(7):403-9
pubmed: 10462204
J Med Imaging (Bellingham). 2020 Mar;7(2):024001
pubmed: 32280728
Carcinogenesis. 2011 Aug;32(8):1143-50
pubmed: 21515914
In Vivo. 2016 09-10;30(5):573-9
pubmed: 27566074
Int J Exp Pathol. 1999 Oct;80(5):271-81
pubmed: 10607018
J Pathol. 2016 Jan;238(2):197-204
pubmed: 26419819
Sci Transl Med. 2016 Aug 31;8(354):354re3
pubmed: 27582061
Regen Ther. 2019 May 10;11:8-16
pubmed: 31193142
Nat Commun. 2015 Feb 27;6:6169
pubmed: 25721094
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
J Clin Invest. 2013 Aug;123(8):3190-200
pubmed: 23908119
Am J Transl Res. 2017 May 15;9(5):2595-2607
pubmed: 28560007
Mol Carcinog. 2007 Oct;46(10):872-85
pubmed: 17455221
Biomaterials. 2019 Aug;213:119202
pubmed: 31132644
Int J Mol Sci. 2021 Aug 12;22(16):
pubmed: 34445363
Exp Cell Res. 2016 Jun 10;344(2):229-40
pubmed: 27090016
Methods Mol Biol. 2013;945:365-82
pubmed: 23097118
Am J Pathol. 2006 Oct;169(4):1415-26
pubmed: 17003496
Nat Med. 2011 Nov 07;17(11):1359-70
pubmed: 22064426
J Clin Oncol. 2007 Jan 10;25(2):209-16
pubmed: 17210942
Tissue Eng Part B Rev. 2008 Mar;14(1):61-86
pubmed: 18454635
Assay Drug Dev Technol. 2014 May;12(4):207-18
pubmed: 24831787
Invest Urol. 1979 Jul;17(1):16-23
pubmed: 447482
Endocrinology. 2013 Feb;154(2):635-45
pubmed: 23295740
ALTEX. 2019 Mar 11;36(3):419-434
pubmed: 30879083
Biomed Eng Online. 2017 May 11;16(1):55
pubmed: 28494781
Anticancer Res. 2015 Jun;35(6):3147-54
pubmed: 26026074
Front Pharmacol. 2020 May 26;11:757
pubmed: 32528290
EMBO Mol Med. 2020 Sep 7;12(9):e11908
pubmed: 32667137
PLoS One. 2008 Aug 27;3(8):e3077
pubmed: 18728788
BMC Cancer. 2008 Nov 04;8:319
pubmed: 18980698
J Natl Cancer Inst. 1973 Nov;51(5):1417-23
pubmed: 4357758
Int J Cancer. 2000 Feb 1;85(3):446-50
pubmed: 10652439
J Urol. 1998 Sep;160(3 Pt 1):932-6
pubmed: 9720590
Cancers (Basel). 2020 Sep 24;12(10):
pubmed: 32987868
J Cancer. 2019 Oct 15;10(24):6095-6104
pubmed: 31762819
Microsyst Nanoeng. 2020 Nov 2;6:99
pubmed: 34567708
Cells Tissues Organs. 2012;196(5):385-97
pubmed: 22739504
Neoplasia. 2008 Aug;10(8):816-27
pubmed: 18683320
Genes Cancer. 2011 Dec;2(12):1085-96
pubmed: 22866200
Int J Cancer. 1992 Feb 20;50(4):665-9
pubmed: 1537635
Trends Biotechnol. 2013 Jun;31(6):347-54
pubmed: 23597659
Tissue Eng Part A. 2021 May;27(9-10):618-630
pubmed: 32873224
Endocrinology. 2000 Sep;141(9):3172-82
pubmed: 10965888
Oncotarget. 2013 Feb;4(2):316-28
pubmed: 23530112
PLoS One. 2010 May 03;5(5):e10431
pubmed: 20454659
J Cell Sci. 2010 Dec 15;123(Pt 24):4195-200
pubmed: 21123617
Prostate. 1993;22(2):93-108
pubmed: 7681207
Cancer Res. 2015 Jun 15;75(12):2411-5
pubmed: 25998619
Drug Discov Today. 2013 Mar;18(5-6):240-9
pubmed: 23073387
Br J Cancer. 1996 Sep;74(6):910-6
pubmed: 8826857
Mutat Res. 2011 Jul-Oct;728(1-2):23-34
pubmed: 21605699
Nat Rev Urol. 2013 Aug;10(8):483-7
pubmed: 23752995
EMBO Rep. 2014 Dec;15(12):1243-53
pubmed: 25381661
Am J Pathol. 2012 Oct;181(4):1126-41
pubmed: 22858156
Cell Death Dis. 2018 Jan 25;9(2):115
pubmed: 29371595
Sci Rep. 2020 Jul 14;10(1):11574
pubmed: 32665693
ALTEX. 2015;32(2):125-36
pubmed: 25742497